A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 24‐week efficacy and safety results from a randomized, double‐blinded trial*-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 24‐week efficacy and safety results from a randomized, double‐blinded trial*

Published:2020-10-25 Issue:6 Volume:184 Page:1047-1058
ISSN:0007-0963
Container-title:British Journal of Dermatology
language:en
Short-container-title:Br J Dermatol

Author:

Blauvelt A.¹^ORCID,Leonardi C.²,Elewski B.³^ORCID,Crowley J.J.⁴,Guenther L.C.⁵,Gooderham M.⁶^ORCID,Langley R.G.⁷,Vender R.⁸^ORCID,Pinter A.⁹^ORCID,Griffiths C.E.M.¹⁰,Tada Y.¹¹,Elmaraghy H.¹²,Lima R.G.¹²,Gallo G.¹²,Renda L.¹²,Burge R.¹²^ORCID,Park S.Y.¹²,Zhu B.¹²,Papp K.¹³^ORCID,

Affiliation:

1. Oregon Medical Research Center Portland OR USA

2. Central Dermatology St Louis MO USA

3. Deparment of Dermatology University of Alabama Birmingham AL USA

4. Bakersfield Dermatology and Skin Cancer Medical Group Bakersfield CA USA

5. Guenther Research Inc London ON Canada

6. SKiN Centre for Dermatology Peterborough ON Canada

7. Dalhousie University Halifax NS Canada

8. Dermatrials Research Inc Hamilton ON Canada

9. Clinic for Dermatology, Venereology and Allergology University Hospital Frankfurt Frankfurt am Main Germany

10. Dermatology Centre Salford Royal HospitalNIHR Manchester Biomedical Research CentreUniversity of Manchester Manchester UK

11. Department of Dermatology Teikyo University School of Medicine Tokyo Japan

12. Eli Lilly and Company Indianapolis IN USA

13. Probity Medical Research, Inc. Waterloo ON Canada

Funder

Eli Lilly and Company

Publisher

Wiley

Subject

Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjd.19509

Reference25 articles.

1. Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials

2. Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials

3. A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 12‐week efficacy, safety and speed of response from a randomized, double‐blinded trial

4. Patient perspectives in the management of psoriasis: Results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey

5. Underdiagnosed and undertreated psoriasis: Nuances of treating psoriasis affecting the scalp, face, intertriginous areas, genitals, hands, feet, and nails

Cited by 70 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Quality of reporting and concordance between sources of adverse events in the treatment of moderate-to-severe psoriasis: a cross-sectional study of RCTs from a Cochrane systematic review;Journal of Clinical Epidemiology;2024-09

2. Treatment strategies for Spondyloarthritis: Implementation of precision medicine – Or “one size fits all” concept?;Autoimmunity Reviews;2024-09

3. IL-17 and IL-23 Inhibitors Have the Fastest Time to Meaningful Clinical Response for Plaque Psoriasis: A Network Meta-Analysis;Journal of Clinical Medicine;2024-08-29

4. Injection site reactions resulting from the use of biological therapy in the treatment of moderate-to-severe plaque psoriasis;Expert Opinion on Drug Safety;2024-08-17

5. Head-to-Head-Studien bei Psoriasis und Psoriasisarthritis;Zeitschrift für Rheumatologie;2024-08-14

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3